Year: 2026
Type: article
Abstract: As reported in the previous issue of Molecular Therapy Oncology, Suppipat in Thailand used the automated closed system (CliniMACS Prodigy, Miltenyi Biotec) to manufacture anti-CD19 chimeric antigen receptor (CAR T) cells to successfully treat 12 patients with diffuse large B cell lymphoma (DLCL).1 The authors report one-year event-free and overall survival of 58.3% and 90%, respectively, at a median total cost of USD 111,231. Patients’ treatment was financially supported by government grants and philanthropic contributions.
Source: Molecular Therapy Oncology
Authors: Marcos de Lima, David Wald
Institutions: The Ohio State University, Case Western Reserve University
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,900
OpenAlex ID: W7225402105